Neuromodulation Therapy for Schizophrenia

(TMSNS Trial)

This trial tests a new form of neuromodulation therapy to determine its effectiveness in improving symptoms like low motivation and difficulty in social interactions for people with schizophrenia. Participants will receive either the actual therapy or a placebo (sham) version, and the study will explore different application methods. The goal is to assess the treatment's safety and effectiveness over a short period. Individuals who have had schizophrenia for at least six months and experience significant negative symptoms might be suitable candidates for this trial. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could lead to new treatment options for schizophrenia.

The trial requires that you have been on a stable medication plan for at least 4 weeks before joining, so you should not stop taking your current medications.

Research has shown that accelerated intermittent theta burst stimulation (iTBS) is generally safe and well-tolerated. In one study, people with schizophrenia showed improvements in their symptoms after receiving this treatment. Another study found that iTBS is a safe method with good potential for treating schizophrenia.

Researchers are excited about accelerated neuromodulation therapy for schizophrenia because it offers a non-invasive approach to managing symptoms. Unlike standard treatments, which often involve antipsychotic medications with various side effects, this therapy uses intermittent Theta Burst Stimulation (iTBS) to target the brain's left dorsolateral prefrontal cortex. The therapy is unique in its use of advanced neuronavigation techniques, such as Neuronavigated Targeting and BEAM-F3 Targeting, to precisely deliver stimulation. This precision may enhance treatment effectiveness and reduce side effects, providing a promising alternative for patients seeking new options.

Research has shown that accelerated neuromodulation therapy, using intermittent theta burst stimulation (iTBS), can reduce the negative symptoms of schizophrenia. In this trial, participants will receive different forms of iTBS targeting the left dorsolateral prefrontal cortex, which aids in decision-making and behavior. One group will receive neuronavigation-guided targeting, another will receive BEAM-F3 targeting, and a third group will receive sham iTBS as a comparator. Studies have found that iTBS can improve social skills and emotional expression. Participants in those studies reported fewer negative symptoms and better social interactions. iTBS is considered safe and may also enhance cognitive abilities like memory and attention. Overall, this treatment shows promise in helping people with schizophrenia.³⁵⁶⁷⁸